CTOs on the Move

Centerfirst

www.center-first.com

 
Centerfirst was founded in early 2004 to help healthcare leaders maximize the value of their call centers.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.center-first.com
  • 5875 Vastle Creek Pkwy, N Dr Suite 240
    Indianapolis, IN USA 46250
  • Phone: 800.291.3379

Executives

Name Title Contact Details

Similar Companies

TriNetX

TriNetX is the global health research network enabling healthcare organizations, biopharmaceutical companies and contract research organizations (CROs) to collaborate, enhance trial design, accelerate recruitment and bring new therapies to market faster. TriNetX combines EMR data such as demographics, diagnoses, procedures, medications, labs, genomics, and deep oncology data with data derived from clinical documentation including discharge summaries, radiology reports, pathology reports, and others, to deliver the industry`s most comprehensive data set for protocol design, feasibility, site selection and patient identification.

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.

Institute for Protein Design

We aim to design a new world of proteins to address 21st century challenges in medicine, energy, and technology.

Harbor Therapeutics

Harbor Therapeutics is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Contrafect

ContraFect is a biotechnology company focused on discovering and developing therapeutic protein and antibody products for life-threatening, drug-resistant infectious diseases, particularly those treated in hospital settings. Due to drug-resistant and newly emerging pathogens, hospital acquired infections are currently the fourth leading cause of death in the United States, following heart disease, cancer and stroke. We intend to address drug-resistant infections using our therapeutic product candidates from our lysin and monoclonal antibody platforms to target conserved regions of either bacteria or viruses (regions that are not prone to mutation). ContraFect's initial product candidates include new agents to treat antibiotic-resistant infections such as MRSA (drug-resistant staphylococcus bacteria) and influenza.